International journal of clinical pharmacology and therapeutics最新文献_第10页

Research progress in targeted therapies for gastric cancer. 胃癌靶向治疗的研究进展。

IF 0.8 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2022-12-01 DOI: 10.5414/CP204250

Min Ye, Li-Juan Xiu, Qing-Qing Ji, Ying-Cheng Zhang, Yu-Wei Sun, Ying Zhao, Dan Wang, Yong-Jin Li, Xiao-Wei Wang, Xiao-Qiang Yue, Da-Zhi Sun

{"title":"Research progress in targeted therapies for gastric cancer.","authors":"Min Ye, Li-Juan Xiu, Qing-Qing Ji, Ying-Cheng Zhang, Yu-Wei Sun, Ying Zhao, Dan Wang, Yong-Jin Li, Xiao-Wei Wang, Xiao-Qiang Yue, Da-Zhi Sun","doi":"10.5414/CP204250","DOIUrl":"https://doi.org/10.5414/CP204250","url":null,"abstract":"Patients with advanced gastric cancer experience rapid disease progression with limited survival, high mortality, and a lack of surgical options. Thus, radiochemotherapy or a combination of chemotherapeutics with targeted therapy is the mainstay of treatment. In comparison to the treatment of other malignant tumors, in gastric cancer, the development of molecularly targeted drugs has been relatively slow. Currently, there are two major classes of molecularly targeted drug regimens that have achieved a certain efficacy in clinical practice: anti-vascular endothelial growth factor (anti-VEGF) therapy and anti-epidermal growth factor receptor (anti-EGFR) therapy. Trastuzumab has been approved as the standard of care for first-line treatment in advanced human epidermal growth factor receptor 2 (HER2)-positive gastric cancer. Ramucirumab in combination with paclitaxel is the recommended regimen for second-line treatment, and apatinib is recommended as third-line treatment. This review summarizes the current status of targeted therapies in the treatment of gastric cancer and gives a perspective on the future.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33489127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Hepatic failure with fatal outcome during pregnancy following administration of a single therapeutic dose of acetominophen: Case report and literature review. 妊娠期间服用单剂量乙酰氨基酚后肝功能衰竭致死性结局:病例报告和文献回顾。

IF 0.8 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2022-11-01 DOI: 10.5414/CP204242

Yu Gao, Rui Zhang, Hua Liang, Yan Huang

{"title":"Hepatic failure with fatal outcome during pregnancy following administration of a single therapeutic dose of acetominophen: Case report and literature review.","authors":"Yu Gao, Rui Zhang, Hua Liang, Yan Huang","doi":"10.5414/CP204242","DOIUrl":"https://doi.org/10.5414/CP204242","url":null,"abstract":"Acetaminophen is generally regarded as a safe antipyretic and analgetic agent and is widely used in cases of pregnancy. However, acetaminophen is also one of the most frequently reported medications in cases of drug overdose. On the other hand, in the few instances described in the literature, where normal doses of acetaminophen administered during pregnancy may have had a fatal outcome, evidence existed pointing to a history of liver disease. It is therefore of interest that the patient in this report who died of liver failure after ingesting standard doses of acetaminophen also suffered from intrahepatic cholestasis during pregnancy although there was no history of liver disease. Other than these instances, there have been no previous reports in the literature of a normal, therapeutic dose of acetaminophen having a fatal outcome in pregnancy. This case emphasizes the need for caution when prescribing acetaminophen during pregnancy to patients with a history of liver disease, regardless of whether the liver function has returned to normal.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33478272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of therapeutic drug monitoring and adherence to imatinib in chronic myeloid leukemia in Japan. 日本慢性髓性白血病治疗药物监测和伊马替尼依从性的流行情况。

IF 0.8 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2022-11-01 DOI: 10.5414/CP204259

Kazuhiro Kawabe, Toshimitsu Nakayama, Noriyasu Fukuoka, Yasutaka Sakamoto, Hirohito Goto, Taiichi Suzuki, Hirofumi Koike, Yukiko Sahashi, Nobuhiro Ooba

{"title":"Prevalence of therapeutic drug monitoring and adherence to imatinib in chronic myeloid leukemia in Japan.","authors":"Kazuhiro Kawabe, Toshimitsu Nakayama, Noriyasu Fukuoka, Yasutaka Sakamoto, Hirohito Goto, Taiichi Suzuki, Hirofumi Koike, Yukiko Sahashi, Nobuhiro Ooba","doi":"10.5414/CP204259","DOIUrl":"https://doi.org/10.5414/CP204259","url":null,"abstract":"Objective: The effectiveness of imatinib, a tyrosine kinase inhibitor recommended for the treatment of chronic myeloid leukemia, is associated with high adherence and trough plasma imatinib concentrations of ~ 1,000 ng/mL. However, adherence and therapeutic drug monitoring (TDM) for imatinib have hardly been reported. This study evaluated the prevalence of TDM and adherence to imatinib for chronic myeloid leukemia in Japan.Materials and methods: Monthly insurance claims data for ~ 5.6 million individuals aged 20 - 74 years between June 1, 2005 and December 31, 2017 were studied. Patients with at least one prescription for imatinib were included to calculate adherence and the annual mean prevalence of TDM for imatinib.Results: A total of 498 patients with 9,620 prescriptions of imatinib were included. After 2013, the number of imatinib prescriptions and the number of patients treated with imatinib were over 1,000 and 200, respectively. The mean annual prevalence of TDM for imatinib was 12.2% (95% confidence interval (CI), 8.1 - 16.1%). Antihyperuricemic drugs and steroids increased the likelihood of TDM. The medication possession ratio for assessment of adherence was 93.5% (95% CI: 91.8 - 95.5%). The annual mean prevalence of TDM for imatinib was low, although adherence was high.Conclusion: To encourage the measurement of plasma concentrations of imatinib in clinical settings, adding a package insert, a summary of product characteristics, and a patient information leaflet regarding the implementation of TDM is justified and warrants further attention.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40600336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-dose ulinastatin reduces postoperative bleeding and provides platelet-protective effects in patients undergoing heart valve replacement surgery. 在接受心脏瓣膜置换术的患者中，大剂量乌司他丁可减少术后出血并提供血小板保护作用。

IF 0.8 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2022-11-01 DOI: 10.5414/CP204219

Yi Lyu, Mengyuan Cao, Cuina Wei, Hao Fang, Xianfu Lu

{"title":"High-dose ulinastatin reduces postoperative bleeding and provides platelet-protective effects in patients undergoing heart valve replacement surgery.","authors":"Yi Lyu, Mengyuan Cao, Cuina Wei, Hao Fang, Xianfu Lu","doi":"10.5414/CP204219","DOIUrl":"https://doi.org/10.5414/CP204219","url":null,"abstract":"Background: The aim of this prospective study was to investigate the effect of a high dose of ulinastatin on platelets and coagulation in patients undergoing mitral valve and/or aortic valve replacement with cardiopulmonary bypass (CPB).Materials and methods: 273 patients were enrolled in this open-label study. According to patients' willingness, 243 patients were assigned to the ulinastatin group and 30 to the control group. In the ulinastatin group, ulinastatin (300,000 U) was given after the induction of anesthesia, ulinastatin (400,000 U) was added to the CPB pump prime, and then ulinastatin (300,000 U) was administered after weaning from CPB. Complete blood count and coagulation function test were conducted 1 day before surgery and on the first postoperative day. Bleeding and other safety events were recorded during hospitalization.Results: Less postoperative major bleeding occurred in the ulinastatin group (0.4 vs. 6.7%, p = 0.03). Moreover, 1 day after CPB, platelet count in the ulinastatin group increased significantly compared to that in the control group (157.7 ± 71.0 vs. 132.1 ± 59.6, p = 0.03). Interestingly and contrary to what was expected, activated partial thromboplastin time (APTT) and prothrombin time (PT) did not differ significantly between the two groups. Ulinastatin application did not cause significant increase in total costs (p = 0.89).Conclusion: In heart valve replacement surgery with CPB, high-dose ulinastatin could reduce postoperative bleeding and promote platelet recovery with no significant additional medical cost.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40705664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elevation of serum creatine kinase induced by anti-thyroid drugs: Two case reports and a literature review. 抗甲状腺药物引起血清肌酸激酶升高:2例报告及文献复习。

IF 0.8 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2022-11-01 DOI: 10.5414/CP204269

Yuqi Si, Fenli Su, Haoxiang Wu, Chuangpeng Shen

引用次数: 0

Effect of mammalian-target-of-rapamycin inhibitors on the cancer risk in patients receiving calcineurin inhibitors: Data mining of a spontaneous reporting database. 哺乳动物靶向雷帕霉素抑制剂对钙调磷酸酶抑制剂患者癌症风险的影响:一个自发报告数据库的数据挖掘。

IF 0.8 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2022-11-01 DOI: 10.5414/CP204277

Takaya Uno, Mitsutaka Takada, Satoshi Yokoyama, Kazuyoshi Kawabata, Kouichi Hosomi

{"title":"Effect of mammalian-target-of-rapamycin inhibitors on the cancer risk in patients receiving calcineurin inhibitors: Data mining of a spontaneous reporting database.","authors":"Takaya Uno, Mitsutaka Takada, Satoshi Yokoyama, Kazuyoshi Kawabata, Kouichi Hosomi","doi":"10.5414/CP204277","DOIUrl":"https://doi.org/10.5414/CP204277","url":null,"abstract":"Objective: Calcineurin inhibitors (CNIs), including cyclosporine and tacrolimus, are associated with an increased cancer risk. However, whether mammalian target of rapamycin inhibitors (mTORis), including sirolimus and everolimus, decrease the cancer risk in patients receiving CNIs remains uncertain. We aimed to determine whether mTORis are associated with a decreased cancer risk in patients receiving CNIs using data mining of a spontaneous adverse reaction database.Materials and methods: Disproportionality analysis was conducted using the U.S. Food and Drug Administration Adverse Event Reporting System database (2004 - 2019) with reporting odds ratio and information component being used to indicate a signal.Results: Data subset analyses indicated that sirolimus and everolimus were not associated with a decreased cancer risk in patients receiving cyclosporine or tacrolimus but were associated with an increased risk of nonmelanoma skin cancer (NMSC) and Kaposi's sarcoma.Conclusion: mTORis are not associated with a decreased cancer risk but are associated with a further increase in the risk of NMSC and Kaposi's sarcoma in patients receiving CNIs. Further studies are necessary to clarify the mechanism underlying the association between mTORis and NMSC or Kaposi's sarcoma.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40362749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes in the first anti-seizure medication prescribed for children and adolescents with epilepsy in a tertiary clinical center in Serbia over two decades. 二十年来，塞尔维亚三级临床中心为患有癫痫的儿童和青少年开的第一批抗癫痫药物的变化。

IF 0.8 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2022-10-01 DOI: 10.5414/CP204236

Ksenija Gebauer-Bukurov, Slobodan Sekulić, Željko Živanović, Željka Nikolašević

引用次数: 1

Lemborexant add-on further improves the effect of galantamine on sleep-wake disorder in Alzheimer's disease. Lemborexant添加物进一步改善了加兰他明对阿尔茨海默病睡眠-觉醒障碍的影响。

IF 0.8 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2022-10-01 DOI: 10.5414/CP204213

Tsukasa Murata, Mayumi Hamada

引用次数: 0

Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient. 肾移植受者中瑞德西韦与免疫抑制剂的药物-药物相互作用。

IF 0.8 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2022-10-01 DOI: 10.5414/CP204239

Toshinori Hirai, Akari Mizuta, Takeshi Sasaki, Kouhei Nishikawa, Takahiro Inoue, Takuya Iwamoto

{"title":"Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient.","authors":"Toshinori Hirai, Akari Mizuta, Takeshi Sasaki, Kouhei Nishikawa, Takahiro Inoue, Takuya Iwamoto","doi":"10.5414/CP204239","DOIUrl":"https://doi.org/10.5414/CP204239","url":null,"abstract":"A 60-year-old man was treated with a regimen of controlled-release tacrolimus (2 mg once daily), everolimus (0.5 mg twice daily), methylprednisolone (4 mg once daily), and mizoribine (100 mg twice daily) as an anti-rejection regimen following living-donor kidney transplantation. One year after transplantation, the recipient was admitted to Mie University Hospital (day X; admission date) to treat coronavirus disease 2019 pneumonia. The latest trough concentrations of tacrolimus and everolimus before admission (day X-65) were 4.5 ng/mL and 4.4 ng/mL, respectively. Since tacrolimus concentration was 4.2 ng/mL on day X+3, the dose was adjusted to 1.5 mg once daily to reach the target concentration of 3.0 ng/mL due to the introduction of remdesivir. After starting remdesivir on day X+4, the increased trough concentrations of tacrolimus on day X+6 (6.9 ng/mL) and everolimus on day X+7 (9.2 ng/mL) were observed, which resulted in dose reduction of tacrolimus (0.5 mg once daily) and discontinuation of everolimus. After discontinuation of remdesivir on day X+9, dose titration of controlled-release tacrolimus and restart of everolimus (0.5 mg twice daily) were performed from day X+15. The dose of controlled-release tacrolimus was titrated and fixed to 2 mg once daily at discharge (day X+21). There was no toxicity due to immunosuppressive agents during hospitalization. This case report indicated that remdesivir might interact with cytochrome P450 3A4 substrates, such as tacrolimus and everolimus, and elevate their blood concentrations under high inflammatory conditions.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40525087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Search for nutritional and inflammatory marker ratios to predict neutropenia in FEC therapy for breast cancer: A retrospective observational study. 寻找营养和炎症标志物比率来预测FEC治疗乳腺癌中性粒细胞减少:一项回顾性观察研究。

IF 0.8 4区医学

International journal of clinical pharmacology and therapeutics Pub Date : 2022-10-01 DOI: 10.5414/CP204264

Toshiki Nakamura, Hajime Matsubara

{"title":"Search for nutritional and inflammatory marker ratios to predict neutropenia in FEC therapy for breast cancer: A retrospective observational study.","authors":"Toshiki Nakamura, Hajime Matsubara","doi":"10.5414/CP204264","DOIUrl":"https://doi.org/10.5414/CP204264","url":null,"abstract":"Objective: Nutritional and inflammatory marker ratios are known to predict response to chemotherapy in breast cancer, but whether they predict adverse effects caused by chemotherapy remains unclear. We investigated whether nutritional and inflammatory marker ratios before starting FEC therapy (5-fluorouracil, epirubicin, and cyclophosphamide) predict grade 4 neutropenia as a serious adverse effect.Materials and methods: 61 patients with breast cancer who started FEC therapy for the first time as preoperative or postoperative chemotherapy were studied. Relevant nutritional and inflammatory marker ratios were compared between patients who developed grade 4 neutropenia (n = 44) and those who did not (n = 17).Results: In univariate analysis, occurrence of neutropenia was related significantly (p < 0.05) to pre-FEC-therapy white blood cell count, platelet count, neutrophil count, lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and modified Glasgow prognostic score. Analysis using cutoff values obtained from receiver operating characteristic curves showed that LMR, NLR, and PLR predicted grade 4 neutropenia. However, multivariate logistic regression analysis identified no independent factor associated with grade 4 neutropenia. A post-hoc power analysis revealed an inadequate sample size.Conclusion: Inflammatory marker ratios, especially PLR, may predict grade 4 neutropenia caused by FEC therapy for breast cancer. Although multivariate analysis identified no independent predictive markers in this study due to inadequate sample size, further prospective large-scale research is needed to examine the usefulness of nutritional and inflammatory marker ratios for predicting adverse effects.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40600337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0